[HTML][HTML] Cost-effectiveness analysis of direct oral anticoagulants vs. vitamin K antagonists in the elderly with atrial fibrillation: insights from the evidence in a real-world …
Y Wu, C Zhang, ZC Gu - Frontiers in Cardiovascular Medicine, 2021 - frontiersin.org
Background: In the clinical setting, the economic benefits of direct oral anticoagulants
(DOACs) in elderly patients with atrial fibrillation (AF) remain unclear. This study aimed to …
(DOACs) in elderly patients with atrial fibrillation (AF) remain unclear. This study aimed to …
Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation
YJ Zhao, L Lin, HJ Zhou, KT Tan, AP Chew… - International journal of …, 2016 - Elsevier
Abstract Background Novel oral anticoagulants (NOACs) expand the treatment options for
patients with atrial fibrillation (AF). Their benefits need to be weighed against the risk–benefit …
patients with atrial fibrillation (AF). Their benefits need to be weighed against the risk–benefit …
[HTML][HTML] Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United …
MB Munir, P Hlavacek, A Keshishian, JD Guo… - PloS one, 2022 - journals.plos.org
Background Oral anticoagulants (OACs) mitigate the risk of stroke in atrial fibrillation (AF)
patients. Objective Elderly AF patients who were treated with OACs (apixaban, dabigatran …
patients. Objective Elderly AF patients who were treated with OACs (apixaban, dabigatran …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2018 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2020 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
[HTML][HTML] Safety outcomes of direct oral anticoagulants in older adults with atrial fibrillation: a systematic review and meta-analysis of (subgroup analyses from) …
K Doni, S Bühn, A Weise, NK Mann, S Hess… - GeroScience, 2024 - Springer
Balancing stroke prevention and risk of bleeding in patients with atrial fibrillation (AF) is
challenging. Direct oral anticoagulants (DOACs) are by now considered standard of care for …
challenging. Direct oral anticoagulants (DOACs) are by now considered standard of care for …
[HTML][HTML] Efficacy and safety of direct oral anticoagulants in elderly patients with atrial fibrillation: a network meta-analysis
K Deng, J Cheng, S Rao, H Xu, L Li, Y Gao - Frontiers in medicine, 2020 - frontiersin.org
Background: Direct oral anticoagulants (DOACs) have been widely used in patients with
atrial fibrillation (AF) for antithrombotic prophylaxis, which were shown to have a favorable …
atrial fibrillation (AF) for antithrombotic prophylaxis, which were shown to have a favorable …
Reduced dose of rivaroxaban and dabigatran vs. vitamin K antagonists in very elderly patients with atrial fibrillation in a nationwide cohort study
L Fauchier, P Blin, F Sacher, C Dureau-Pournin… - EP …, 2020 - academic.oup.com
Aims The real-life benefits and risks of the non-vitamin K antagonist oral anticoagulants for
stroke prevention in very elderly patients with atrial fibrillation (AF) are still debated. Methods …
stroke prevention in very elderly patients with atrial fibrillation (AF) are still debated. Methods …
[HTML][HTML] Direct oral anticoagulants vs. vitamin-K antagonists in the elderly with atrial fibrillation: a systematic review comparing benefits and harms between …
NN Shen, Y Wu, N Wang, LC Kong, C Zhang… - Frontiers in …, 2020 - frontiersin.org
Background: The publication of high-quality observational studies (OSs) has fueled
reassessment of the treatment effects of direct oral anticoagulants (DOACs) in the elderly …
reassessment of the treatment effects of direct oral anticoagulants (DOACs) in the elderly …
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients≥ 75 and< …
S Deitelzweig, A Amin, Y Jing… - Journal of Medical …, 2013 - Taylor & Francis
Objectives: Based on clinical trials the oral anticoagulants (OACs) apixaban, dabigatran,
and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation …
and rivaroxaban are efficacious for reducing stroke risk for non-valvular atrial fibrillation …
相关搜索
- elderly patients atrial fibrillation
- cost effectiveness atrial fibrillation
- oral anticoagulants fibrillation patients
- meta analysis atrial fibrillation
- oral anticoagulants health care
- oral anticoagulants medicare population
- cost effectiveness elderly patients
- rivaroxaban and dabigatran atrial fibrillation
- oral anticoagulants effectiveness and safety
- safety outcomes atrial fibrillation
- clinical profile atrial fibrillation
- older adults atrial fibrillation
- meta analysis elderly patients
- reduced dose atrial fibrillation
- propensity score atrial fibrillation
- oral anticoagulants atrial fibrillation